Tax

EQS-News: Preliminary unaudited financial figures for 2023 - DF Group holds its own in a difficult market environment

Retrieved on: 
Wednesday, April 10, 2024
EUR, DF, Federal Financial Supervisory Authority, Tax, Marketing, Bank statement, Policy, Annual report

Cologne, March 27, 2024 - DF Deutsche Forfait AG (ISIN: DE000A2AA204) (DF AG) has closed a difficult and challenging financial year 2023 with a positive result according to preliminary unaudited figures.

Key Points: 
  • Cologne, March 27, 2024 - DF Deutsche Forfait AG (ISIN: DE000A2AA204) (DF AG) has closed a difficult and challenging financial year 2023 with a positive result according to preliminary unaudited figures.
  • The preliminary business volume rose to EUR 182.1 million in the financial year 2023 (previous year: EUR 145.8 million).
  • At EUR 8.4 million, the preliminary gross profit for 2023 is in line with the forecast adjusted in July 2023.
  • According to preliminary figures, DF AG's cash and cash equivalents amounted to EUR 41.9 million as of 31 December 2023.

EQS-News: APONTIS PHARMA expects profitable growth again in 2024

Retrieved on: 
Wednesday, April 10, 2024
EUR, Annual report, Tax, Marketing, Ticker, Growth, Physician, Depreciation, Pharmaceutical industry

APONTIS PHARMA closed the 2023 financial year with a consolidated net loss of EUR 11.3 million (2022: consolidated net income of EUR 2.7 million).

Key Points: 
  • APONTIS PHARMA closed the 2023 financial year with a consolidated net loss of EUR 11.3 million (2022: consolidated net income of EUR 2.7 million).
  • Bruno Wohlschlegel, Chief Executive Officer of APONTIS PHARMA AG: “The 2023 financial year was characterized by significant changes for APONTIS PHARMA.
  • Following the successful implementation of the performance and efficiency improvement program earlier than planned, APONTIS PHARMA has laid the foundations for future profitable growth in Single Pill combinations.
  • As such, we launched our 15th Single Pill combination on the German market in March and continue to see considerable growth potential for Single Pill combinations from APONTIS PHARMA.

EQS-News: 2023 financial year: ElringKlinger records improved earnings and high nomination volume for e-mobility applications

Retrieved on: 
Wednesday, April 10, 2024
EUR, Annual, Annual report, Uncertainty, Tax, Forecasting, Growth, Supervisory board, ElringKlinger, Supervision, Bank statement, BMW, Housing, Depreciation, Film industry

This will be driven in particular by the high volume of nominations that ElringKlinger received for e-mobility applications in 2023."

Key Points: 
  • This will be driven in particular by the high volume of nominations that ElringKlinger received for e-mobility applications in 2023."
  • In the financial year just ended, the Group managed to increase revenue by 2.7% to EUR 1,847.1 million (2022: EUR 1,798.4 million).
  • Thus, net income attributable to shareholders of ElringKlinger AG amounted to EUR 39.3 million in 2023 (2022: EUR -89.1 million).
  • This will be driven in particular by the high volume of nominations that ElringKlinger received for e-mobility applications in 2023."

EQS-News: JOST closes fiscal year 2023 successfully and proposes a dividend of EUR 1.50 per share

Retrieved on: 
Wednesday, April 10, 2024
Electricity, Annual, Tax, Transport, Neu-Isenburg, Growth, Supervisory board, CFO, EPS, Carbon footprint, Acquisition, Adjustment, ROCE, Investment, Sustainability, PPA, Lithium

Consolidated sales declined slightly in 2023 by 1.2% to EUR 1,249.7 million year-over-year (2022: EUR 1,264.6 million).

Key Points: 
  • Consolidated sales declined slightly in 2023 by 1.2% to EUR 1,249.7 million year-over-year (2022: EUR 1,264.6 million).
  • As a result, adjusted EBIT rose by 13.7% to EUR 140.8 million in fiscal year 2023, strongly outpacing sales (2022: EUR 123.8 million).
  • The net financial result declined by EUR 12.7 million to EUR -21.3 million in 2023 (2022: EUR -8.6 million).
  • JOST strongly increased its free cash flow to EUR +112.3 million in 2023 compared to 2022 (2022: EUR +23.7 million).

EQS-News: 1&1 with successful fiscal year 2023

Retrieved on: 
Wednesday, April 10, 2024
Tax, Montabaur, Growth, Supervisory board, Network, EPS, Investment, Depreciation, Access, 1&1 AG, Beauty salon

Revenue rose in 2023 by 3.4 percent to €4,096.7 million (2022: €3,963.7 million).

Key Points: 
  • Revenue rose in 2023 by 3.4 percent to €4,096.7 million (2022: €3,963.7 million).
  • EBITDA 2023 (earnings before interest, taxes, depreciation and amortisation) at €653.8 million (2022: €693.3) is in line with the company's forecast.
  • EBIT amounted to €455.8 million (2022: €534.9 million) in 2023, as expected 14.8 percent below previous year's figure.
  • Assuming 176.3 million shares entitled to dividend (as per 31/12/2022), this would result in a total disbursement of €8.8 million for fiscal 2022.

EQS-News: H&R GmbH & Co. KGaA publishes Annual Report 2023

Retrieved on: 
Wednesday, April 10, 2024
EUR, Tax, Depreciation

H&R GmbH & Co. KGaA (H&R KGaA; ISIN DE000A2E4T77) achieved an operating result (EBITDA - consolidated earnings before income taxes, other financial income and expenses as well as depreciation, amortization, impairment and write-ups of intangible assets and property, plant and equipment) of EUR 92.7 million for financial year 2023 (2022: EUR 124.9 million); (for the other earnings levels, see the "Key figures for H&R KGaA" table below).

Key Points: 
  • H&R GmbH & Co. KGaA (H&R KGaA; ISIN DE000A2E4T77) achieved an operating result (EBITDA - consolidated earnings before income taxes, other financial income and expenses as well as depreciation, amortization, impairment and write-ups of intangible assets and property, plant and equipment) of EUR 92.7 million for financial year 2023 (2022: EUR 124.9 million); (for the other earnings levels, see the "Key figures for H&R KGaA" table below).
  • Below the line, consolidated net income attributable to shareholders amounted to EUR 10.6 million (2022: EUR 42.7 million).
  • This was EUR 223.7 million less than in the previous year (2022: EUR 1,576.0 million) due to price and volume factors.
  • Key figures for H&R KGaA:

EQS-News: STS Group AG publishes annual report 2023 - Forecast well met thanks to positive development in all regions

Retrieved on: 
Wednesday, April 10, 2024
Annual, Annual report, Tax, General Standard, Growth, Frankfurt Stock Exchange, SMC, STS Group, Plastic, Depreciation, Material

The results confirm that the STS Group AG has well met its annual forecast for sales revenue, EBITDA and EBITDA margin in the 2023 financial year.

Key Points: 
  • The results confirm that the STS Group AG has well met its annual forecast for sales revenue, EBITDA and EBITDA margin in the 2023 financial year.
  • Alberto Buniato, CEO of STS Group AG: "We are on the right track with the STS Group.
  • The strong growth of 18.2% is in line with the annual forecast and was driven by all three segments.
  • The Annual Report 2023 of STS Group AG will be available for download on April 11, 2024 at https://www.sts.group/investor-relations/publications .

EQS-News: Krones plans to pay dividend of €2.20 per share for successful 2023 financial year

Retrieved on: 
Wednesday, April 10, 2024
Annual, Tax, EBT, Science Based Targets initiative, Growth, Supervisory board, Carbon accounting, Policy, Acquisition, Science, ROCE, Annual report, Depreciation, Krones

The steeply rising demand for resource-efficient, low-emission machinery, systems and solutions will contribute significantly to the continuation of Krones’ profitable growth course.

Key Points: 
  • The steeply rising demand for resource-efficient, low-emission machinery, systems and solutions will contribute significantly to the continuation of Krones’ profitable growth course.
  • Alongside digitalisation and service quality, sustainability is a strategic focus for Krones and is the most important driver of innovation and growth.
  • Krones increased revenue by 12.2% in the financial year 2023 compared to 2022, from €4,209.3 million to €4,720.7 million.
  • The company thus exceeded the upgraded growth target of 11% to 13% published in July 2023 (previously: 8% to 11%).

EQS-News: IKB Deutsche Industriebank AG figures for the 2023 financial year: Solid figures achieved in a difficult environment

Retrieved on: 
Wednesday, April 10, 2024
ESF, Tax, IKB, Pressure, Risk management, Growth, Environment, Risk, Pension, IKB Deutsche Industriebank, Bank, Sale, Acquisition, Common equity, Depreciation, Administration, NPL, EDB, KfW, Corporation

IKB Deutsche Industriebank AG figures for the 2023 financial year: Solid figures achieved in a difficult environment

Key Points: 
  • IKB Deutsche Industriebank AG figures for the 2023 financial year: Solid figures achieved in a difficult environment
    The issuer is solely responsible for the content of this announcement.
  • IKB Deutsche Industriebank AG figures for the 2023 financial year: Solid figures achieved in a difficult environment
    Ample liquidity with free available liquidity reserve of €1.4 billion (previous year: €1.2 billion)
    Dr Michael Wiedmann, Chairman of the Board of Managing Directors of IKB: “We have met our annual targets and are on track to achieving our medium-term goals.
  • 2023 was largely characterised by the increase in market interest rates against a difficult economic backdrop.
  • Table: IKB income statement for the 2023 financial year (Group, in accordance with German commercial law)

EQS-News: Biotest AG increased sales by 32% in the financial year 2023

Retrieved on: 
Wednesday, April 10, 2024
Primary immunodeficiency, PLI, Tax, EBT, Growth, Biologics license application, Dreieich, Partnership, Patient, Research, Grifols, Management, Technology transfer, Disclosure, PID, Annual report, Next Level, S.A, Birth, FDA, BLA, Fibrinogen, Factor

In the financial year 2023, the Biotest Group generated revenue of € 684.6 million compared with € 516.1 million in the previous year.

Key Points: 
  • In the financial year 2023, the Biotest Group generated revenue of € 684.6 million compared with € 516.1 million in the previous year.
  • The consolidated EBIT result in the 2023 financial year of € 143.5 million improved considerably compared with € -16.6 million in the previous year.
  • In September 2023, Biotest reached an important milestone in the marketing authorisation process for Yimmugo® in the USA.
  • The 2023 Annual Report and the 2023 Sustainability Report are available on the company's website.